BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34637052)

  • 1. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
    Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis.
    Grymonprez M; Vanspranghe K; Capiau A; Boussery K; Steurbaut S; Lahousse L
    Br J Clin Pharmacol; 2022 Jul; 88(7):3039-3051. PubMed ID: 35132677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.
    Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
    J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
    Grymonprez M; Carnoy L; Capiau A; Boussery K; Mehuys E; De Backer TL; Steurbaut S; Lahousse L
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):722-730. PubMed ID: 37791408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.
    Harskamp RE; Teichert M; Lucassen WAM; van Weert HCPM; Lopes RD
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):615-623. PubMed ID: 31520256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies.
    Guo Z; Ding X; Ye Z; Chen W; Chen Y
    Clin Cardiol; 2021 Jul; 44(7):917-924. PubMed ID: 34013988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis.
    Zhou Y; He W; Zhou Y; Zhu W
    J Thromb Thrombolysis; 2020 Aug; 50(2):311-317. PubMed ID: 31792707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients (≥80 years of age) with atrial fibrillation: systematic review and meta-analysis.
    Kang F; Su L; Fan S; Lv L; Luo B
    Intern Med J; 2023 Sep; 53(9):1524-1532. PubMed ID: 37178051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
    Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
    Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
    [No Abstract]   [Full Text] [Related]  

  • 17. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review.
    Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W
    Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
    Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
    Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.